|
31 Jan 2019 |
Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
|
|
30 Jan 2019 |
Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents
|
|
29 Jan 2019 |
Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
|
|
24 Jan 2019 |
Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests
|
|
24 Jan 2019 |
Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine
|
|
21 Jan 2019 |
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and Regeneron’s Cemiplimab in Oropharyngeal Cancer
|
|
17 Jan 2019 |
United Neuroscience Announces Positive Top-Line Results from Phase 2a Clinical Study of UB-311 Vaccine in Patients with Alzheimer's Disease
|
|
17 Jan 2019 |
AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial
|
|
17 Jan 2019 |
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
|
|
15 Jan 2019 |
FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination
|
|
08 Jan 2019 |
PrimeVax Immuno-Oncology Receives IND Permission From FDA
|
|
07 Jan 2019 |
Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
|
|
03 Jan 2019 |
Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
|
|
30 Dec 2018 |
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax
|
|
27 Dec 2018 |
FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
|
|
22 Dec 2018 |
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
|
|
22 Dec 2018 |
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
|
|
21 Dec 2018 |
Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis
|
|
20 Dec 2018 |
Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods
|
|
20 Dec 2018 |
HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus
|
|
20 Dec 2018 |
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
|
|
20 Dec 2018 |
ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center
|
|
19 Dec 2018 |
Dengvaxia® vaccine approved for prevention of dengue in Europe
|
|
17 Dec 2018 |
Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
|
|
15 Dec 2018 |
VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma
|
